A phase III clinical trial showed that mRNA-1083, a multicomponent mRNA vaccine targeting seasonal influenza and SARS-CoV-2, demonstrated noninferior immunogenicity compared to standard-of-care vaccines in adults aged 50 and older, with superior immune responses against multiple vaccine-matched strains in some subgroups. The trial involved 8,015 participants and found that mRNA-1083 induced higher immune responses against influenza and SARS-CoV-2, with an acceptable safety profile.

Source: JAMA